Ainos
Open
$1.92
Prev. Close
$1.92
High
$1.92
Low
$1.92
Market Snapshot
$13.88M
-1.0
-1.72
$20.73K
44
Ainos, Inc. is a diversified medtech company, which engages in the development of medical technologies for point-of-care testing and safe and novel medical treatment for a broad range of disease indications. The company is headquartered in Houston, Texas and currently employs 41 full-time employees. Its AI Nose platform and smell language model (SML) digitize scent into Smell ID, a machine-readable data, powering applications across robotics, smart factories, and healthcare. The company is also developing VELDONA, an oral low-dose interferon therapy targeting rare diseases, autoimmune diseases, infectious diseases, and animal health. Its pipeline includes drug candidates for treating oral warts for human immunodeficiency virus seropositive patients, Sjogren’s syndrome, and feline chronic gingivostomatitis, a cat oral infection. Its product pipeline includes VELDONA Pet, VELDONA human drugs, AI Nose - NISD co-development, AI Nose industrial and robotics application, VOC POCT, VOC POCT Ainos Pen, VOC POCT CHS430, and Synthetic RNA (SRNA). VOC POCT-Ainos Pen is a device intended to be a cloud-connected, multipurpose, portable breath analyzer that is intended to monitor health conditions.
Ainos faces competitive pressure as Summit Therapeutics showcases superior performance metrics, potentially impacting Ainos' market position within the pharmaceutical and biotechnology industry.
Ainos, Inc. is a diversified medtech company, which engages in the development of medical technologies for point-of-care testing and safe and novel medical treatment for a broad range of disease indications. The company is headquartered in Houston, Texas and currently employs 41 full-time employees. Its AI Nose platform and smell language model (SML) digitize scent into Smell ID, a machine-readable data, powering applications across robotics, smart factories, and healthcare. The company is also developing VELDONA, an oral low-dose interferon therapy targeting rare diseases, autoimmune diseases, infectious diseases, and animal health. Its pipeline includes drug candidates for treating oral warts for human immunodeficiency virus seropositive patients, Sjogren’s syndrome, and feline chronic gingivostomatitis, a cat oral infection. Its product pipeline includes VELDONA Pet, VELDONA human drugs, AI Nose - NISD co-development, AI Nose industrial and robotics application, VOC POCT, VOC POCT Ainos Pen, VOC POCT CHS430, and Synthetic RNA (SRNA). VOC POCT-Ainos Pen is a device intended to be a cloud-connected, multipurpose, portable breath analyzer that is intended to monitor health conditions.
Recently from Cashu
It appears that you haven't provided any content to summarize. Please share the text you'd like me to summarize, and I'll be happy to help!
Sure, please provide the text you would like me to summarize.
Please provide the content related to Ainos for summarization.
It appears that you have not provided the specific content to be summarized. Please share the information or text regarding Ainos, and I will be glad to help create a relevant article based on your re…
Please provide the content you'd like summarized, and I'll create a title for you.
Sure, I can assist with that. Please provide the content that you would like summarized.
Ainos Advances Diagnostic Technology with Innovative Non-Invasive Health Monitoring Device Development
Ainos Advances in Diagnostic Technology with New Product Development Ainos, a company focused on innovative diagnostic solutions, announces significant progress in its product development aimed at enh…